1020038-42-9 Usage
Uses
Used in Pharmaceutical Synthesis:
Imidazo[1,2-a]pyridine-2-carboxylic acid, 7-chlorois used as a key intermediate in the synthesis of various pharmaceuticals and bioactive molecules. Its unique chemical structure allows for the development of new drugs with potential therapeutic applications.
Used in Medicinal Chemistry Research:
Imidazo[1,2-a]pyridine-2-carboxylic acid, 7-chloroserves as a valuable research tool in medicinal chemistry, enabling scientists to explore its pharmacological and biological properties. Its potential as a lead compound in drug discovery can be further investigated through various chemical modifications and biological assays.
Used in Drug Discovery:
Imidazo[1,2-a]pyridine-2-carboxylic acid, 7-chlorois utilized in drug discovery processes to identify novel therapeutic agents with potential applications in treating various diseases and conditions. Its unique structure and properties make it a promising candidate for the development of new drugs with improved efficacy and selectivity.
Used in Chemical Libraries:
Imidazo[1,2-a]pyridine-2-carboxylic acid, 7-chlorocan be incorporated into chemical libraries for high-throughput screening and virtual screening studies. Its presence in such libraries allows researchers to evaluate its potential as a starting point for the development of new drugs and to identify potential lead compounds for further optimization.
Check Digit Verification of cas no
The CAS Registry Mumber 1020038-42-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,2,0,0,3 and 8 respectively; the second part has 2 digits, 4 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1020038-42:
(9*1)+(8*0)+(7*2)+(6*0)+(5*0)+(4*3)+(3*8)+(2*4)+(1*2)=69
69 % 10 = 9
So 1020038-42-9 is a valid CAS Registry Number.
1020038-42-9Relevant articles and documents
BICYCLIC HETEROARYLS AS KINASE INHIBITORS
-
, (2011/05/06)
The invention is directed to heteroaryl compounds useful as inhibitors of various kinase enzymes. In various embodiments, the invention provides a heteroaryl compound having inhibitory bioactivity with respect to a Rho kinase, an AKT kinase, a p70S6K kinase, a LIM kinase, an IKK kinase, a Flt kinase, an Aurora kinase, or a Src kinase, or any combination thereof. Compounds of the invention include bicyclic heteroaryl compounds of formula (I), which can contain a bridging nitrogen atom at a ring junction. The invention further provides methods of synthesis of compounds of the invention, pharmaceutical compositions, pharmaceutical combinations, and methods of treatment of malconditions using compounds of the invention.
Design, synthesis, and SAR of cis-1,2-diaminocyclohexane derivatives as potent factor Xa inhibitors. Part I: Exploration of 5-6 fused rings as alternative S1 moieties
Yoshikawa, Kenji,Yokomizo, Aki,Naito, Hiroyuki,Haginoya, Noriyasu,Kobayashi, Shozo,Yoshino, Toshiharu,Nagata, Tsutomu,Mochizuki, Akiyoshi,Osanai, Ken,Watanabe, Kengo,Kanno, Hideyuki,Ohta, Toshiharu
scheme or table, p. 8206 - 8220 (2010/04/06)
A series of cis-1,2-diaminocyclohexane derivatives were synthesized with the aim of optimizing previously disclosed factor Xa (fXa) inhibitors. The exploration of 5-6 fused rings as alternative S1 moieties resulted in two compounds which demonstrated improved solubility and reduced food effect compared to the clinical candidate, compound A. Herein, we describe the synthesis and structure-activity relationship (SAR), together with the physicochemical properties and pharmacokinetic (PK) profiles of some prospective compounds.
